Search
for
Sort by
Research 91–120 of 161
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- Hair regrowth in alopecia areata and re‐pigmentation in vitiligo in response to treatment: Commonalities and differences
- A review of Janus kinase inhibitor use in scarring alopecia
- Patient preferences in the treatment of alopecia areata: A review of the literature
- Short Snips: YouTube Shorts Recommendations for Hair Loss and Alopecia
- 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- 75993 Safety of Janus kinase inhibitors for treatment of alopecia areata
- Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO ‐2b/3 and ALLEGRO ‐ LT Clinical Studies for Alopecia Areata
- Irish dermatologists’ experience with JAK inhibitors in alopecia areata
- Insights into the Diagnostics and Therapeutics of Alopecia Areata—An Indian Context
- Caffeine Supplementation and Hair: A Systematic Review
- Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
- Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy
- BH19 ‘JAK in the box?’ Long-term safety concerns with oral Janus kinase inhibitors for alopecia areata
- Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
- Efficacy and Safety of Long‐Term Azathioprine Therapy for Severe Alopecia Areata: A 10‐Year Cohort Study
- Efficacy, safety and tolerability of drugs for alopecia: a comprehensive review
- Alopecia Universalis: Never Give Up?
- Pediatric and Adolescent Alopecia Areata Treated with JAK Inhibitors: Balancing Efficacy and Safety Across Clinical Trials
- Aim to alleviate alopecia areata with newly available agents
- 69 Risk-benefit appraisal of systemic JAK inhibitors for alopecia areata: a comprehensive meta-analysis assessing safety and adverse effects
- Alopecia Areata: An Updated Review for 2023
- Comparison of Current International Guidelines for the Management of Alopecia Areata—Comprehensive Review
- JAK Inhibitors in African American Patients With Alopecia Areata: A Case Series
- Deciphering the Complex Immunopathogenesis of Alopecia Areata
- Alopecia Areata: Pathogenesis, Diagnosis, and Therapies
- Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024
- Baricitinib for the Treatment of Alopecia Areata
- Immune therapies for alopecia areata: evidence and new perspectives
- II Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata